Prospective performance of the International Working Group 2023 and the International Prognostic Scoring System - Molecular in a phase II trial of guadecitabine in higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia
Blood Neoplasia(2024)
摘要
Guadecitabine (SGI-110) is a dinucleotide form of decitabine that has been studied in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Here we present the results of a single center phase II trial of this agent for patients with higher-risk MDS or CMML. Guadecitabine was administered at a dose of 60 mg/kg subcutaneously for five days. Of 100 enrolled patients, 82% had MDS. Median age was 69 years, International Prognostic Scoring System (IPSS) was intermediate-2 in 78% and high in 14%. Thirty-eight percent had complex cytogenetics and 32% had TP53mut. By IWG-2006 criteria, 25% achieved complete remission (CR), 30% marrow CR, and 33% no response (NR). Common grade 3 events were febrile neutropenia (32%) and infection (25%). Mortality rate at 4 and 8 weeks was 0% and 4%, respectively. Median overall survival (mOS) was 16.8 months. Transplanted patients (21%) had a mOS of 46.6 months. We then reanalyzed this dataset using IPSS-Molecular and International Working Group (IWG) 2023 response criteria. By IPSS-M, 60% of patients were classified as very high risk and 27% as high. By IWG-2023, overall response rate (ORR) was 52%, 30% CR, 14% CR with limited count recovery (CRL), with 42% no response (NR). IPSS-M provided adequate risk stratification at enrollment. Patients classified as mCR had widely different outcomes when reclassified by IWG-2023. In conclusion, SGI-110 was active in high risk MDS but survival is unlikely to be superior to current hypomethylating agents. The study is registered as NCT02131597.
更多查看译文
关键词
myelodysplastic syndrome,response criteria,prognostic systems
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要